Vanda Pharmaceuticals Inc.
VNDA Healthcare Biotechnology
Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.
Follow VNDA
Vanda Pharmaceuticals Inc. (VNDA) Piotroski F-score
Vanda Pharmaceuticals Inc.'s Piotroski F-score for fiscal 2025 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 3 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 2 | (1.00) |
| FY2024 | 3 | (2.00) |
| FY2023 | 5 | 1.00 |
| FY2022 | 4 | (2.00) |
| FY2021 | 6 | 0.00 |
| FY2020 | 6 | 2.00 |
| FY2019 | 4 | (3.00) |
| FY2018 | 7 | 2.00 |
| FY2017 | 5 | (1.00) |
| FY2016 | 6 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (38.51%) | (2.90%) | Fail | 0 |
| Positive operating cash flow | (109.44m) | (15.76m) | Fail | 0 |
| Rising return on assets | (38.51%) | (2.90%) | Fail | 0 |
| Cash flow above net income | 111.03m | 3.14m | Pass | 1 |
| Falling long-term leverage | 0.01 | 0.00 | Fail | 0 |
| Rising current ratio | 2.39 | 4.39 | Fail | 0 |
| No new shares issued | 58,930,000 | 58,149,000 | Fail | 0 |
| Rising gross margin | 93.96% | 94.31% | Fail | 0 |
| Rising asset turnover | 0.38 | 0.30 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| LCTX Lineage Cell Therapeutics, Inc. compare | 5 |
| IKT Inhibikase Therapeutics, Inc. compare | 3 |
| VNDA Vanda Pharmaceuticals Inc. | 2 |
| ACIU AC Immune compare | 2 |
| ABEO Abeona Therapeutics Inc. compare | — |
| PRLD Prelude Therapeutics Incorporated compare | — |
| XFOR X4 Pharmaceuticals, Inc. compare | — |
| CABA Cabaletta Bio, Inc. compare | — |
| RCKT Rocket Pharmaceuticals, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover